Oxford Nanopore Technologies PLC on Tuesday said it has signed a new strategic collaboration to advance plasmid sequencing beyond legacy methods, and an expanded multi-year, multi-million dollar contract with the US’s Plasmidsaurus Inc.

Oxford Nanopore is based in Oxford, England, and specialises in DNA and RNA sequencing technologies.

Oxford Nanopore said it has signed a new strategic collaboration to advance plasmid sequencing beyond legacy methods, as well as an expanded ‘multi-year, multi-million dollar global contract’ with Los Angeles-based Plasmidsaurus.

‘Plasmidsaurus’s whole-plasmid sequencing is used by researchers and industry professionals around the world for a broad spectrum of applications, from basic research to industrial applications, gene therapy, vaccine development, genetic engineering and more. Its sequencing capabilities are based on Oxford Nanopore’s real-time, long-read sequencing technology, which has enabled Plasmidsaurus to set new standards for quality and speed, delivering overnight results and richer datasets that unlock more accurate, comprehensive, and reliable insights,’ the company explained.

Plasmidsaurus, which has nine labs open in three countries, has been an Oxford Nanopore customer since 2021.

Chief Executive Gordon Sanghera said: ‘By collaborating with Plasmidsaurus, we are advancing the fields of synthetic biology and biotechnology through the unique capabilities of nanopore technology that are not possible with legacy methods. Our joint efforts will drive significant market growth and deliver best-in-class sequencing services to a global audience.’

Shares in Oxford Nanopore were down 2.1% to 117.93 pence each in London on Tuesday morning.

Copyright 2024 Alliance News Ltd. All Rights Reserved.